Orexigen Therapeutics Inc

Orexigen Therapeutics — JP Morgan Healthcare Conference 2015

22 slides from Orexigen Therapeutics's conference presentation, Jan 12, 2015

  1. Slide 1: JP Morgan Healthcare Conference January 2015

    Slide 1: JP Morgan Healthcare Conference January 2015

    JP Morgan Healthcare Conference January 2015 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    For investor purposes only – not for use in product promotion Forward Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. and its recently approved product, Contrave. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “wil

  3. Slide 3: 2014 was a Transformational Year for Orexigen

    Slide 3: 2014 was a Transformational Year for Orexigen

    For investor purposes only – not for use in product promotion US approval of Contrave ® (naltrexone HCl / bupropion HCl extended-release) US launch Positive CHMP opinion for Mysimba™ (naltrexone HCl / bupropion HCl prolonged- release) Balance sheet strengthened – $100 million in milestones received

  4. Slide 4: Orexigen's First Approved Product

    Slide 4: Orexigen's First Approved Product

    For investor purposes only – not for use in product promotion Orexigen’s First Approved Product Full Prescribing Information, including Medication Guide, for Contrave is available at http://www.contrave.com/ .

  5. Slide 5: Contrave Indication and Important Safety Information

    Slide 5: Contrave Indication and Important Safety Information

    For investor purposes only – not for use in product promotion For investor purposes only – not for use in product promotion INDICATION: Contrave is approved by the FDA for use as an adjunct to a reduced- calorie diet and increased physical activity for chronic weight management in adults with an ini

  6. Slide 6: The Obesity Epidemic is One of the Largest Public Health Challenges

    Slide 6: The Obesity Epidemic is One of the Largest Public Health Challenges

    For investor purposes only – not for use in product promotion $2 trillion direct economic burden worldwide – 2.8% of global GDP May reduce life expectancy by up to 8 years 3.4 million deaths annually directly attributable to obesity and overweight The Obesity Epidemic is One of the Largest Public He

  7. Slide 7: Favorable Global Action in the Fight against Obesity

    Slide 7: Favorable Global Action in the Fight against Obesity

    For investor purposes only – not for use in product promotion Favorable Global Action in the Fight against Obesity AMA recognized obesity as a disease Treat and Reduce Obesity Act had strong support and reintroduction planned in new Congress AACE guidelines stress importance of weight loss (includin

  8. Slide 8: The Obesity Pharmaceutical Market is Rapidly Developing

    Slide 8: The Obesity Pharmaceutical Market is Rapidly Developing

    For investor purposes only – not for use in product promotion The Obesity Pharmaceutical Market is Rapidly Developing In Europe, Mysimba™ is 1 st new drug with positive CHMP opinion in nearly a decade will be educating HCPs about obesity treatments SALES REPS DRUGS RECENTLY APPROVED BY FDA Large CV

  9. Slide 9: Weight Loss is a Medical Imperative in Obese Patients with Diabetes and Prediabetes

    Slide 9: Weight Loss is a Medical Imperative in Obese Patients with Diabetes and Prediabetes

    382 m 316 m With diabetes With prediabetes Xendos Trial Weight Loss at one year 4.0 % Weight Loss at one year relative reduction in progression to diabetes 37 % Costs $281 B $144 B $612 B Deaths 198,000 537,000 4.9 M DPP Study 4.3 % relative reduction in progression to diabetes 39 % “The primary goa

  10. Slide 10: Contrave: A Differentiated US Launch

    Slide 10: Contrave: A Differentiated US Launch

    Resourcing Targeting Positioning Complete Approach For investor purposes only – not for use in product promotion Contrave ® : A Differentiated US Launch 900 sales representatives, market leading SOV Large experienced managed care organization Significant marketing budget 75,000 physicians 50% curren

  11. Slide 11: Contrave Demonstrated Meaningful Efficacy in Phase 3

    Slide 11: Contrave Demonstrated Meaningful Efficacy in Phase 3

    Weight loss over time in the completer population: COR-I Trial Combining Contrave with intensive BMOD drove more weight loss (COR-BMOD completer analysis) For investor purposes only – not for use in product promotion Contrave ® Demonstrated Meaningful Efficacy in Phase 3 ITT-LOCF -2 -4 -6 -8 -10 -12

  12. Slide 12: Pricing Strategy Facilitates Adoption and Access

    Slide 12: Pricing Strategy Facilitates Adoption and Access

    For investor purposes only – not for use in product promotion Pricing Strategy Facilitates Adoption and Access for both Covered and Cash Paying Patient Progressive Savings Designed to Help Reduce Patient Out of Pocket Costs $55 $70 $45 $60 Commercially covered Non-covered/ cash pay Months 1 & 2 Mont

  13. Slide 13: Scale Down Provides Personalized Weight Management Support

    Slide 13: Scale Down Provides Personalized Weight Management Support

    For investor purposes only – not for use in product promotion Program entails 4 easy steps – Complete survey which enables personalized feedback – Weigh-in daily on a wireless-enabled scale – Receive text-based personalized feedback from Scale Down after weigh-in – Receive weekly lessons via email t

  14. Slide 14: Early Launch Results are Encouraging

    Slide 14: Early Launch Results are Encouraging

    For investor purposes only – not for use in product promotion Early Launch Results are Encouraging Source: IMS Data Christmas / NY Thanksgiving Calling on writers and non writers with early success in both Reps are experiencing good access with long call times 900 reps provide dominant share of voic

  15. Slide 15: The US Obesity Pharmacotherapy Market is Growing with Branded Products

    Slide 15: The US Obesity Pharmacotherapy Market is Growing with Branded Products

    Growth in total anti-obesity Rxs Growth in branded anti-obesity Rxs For investor purposes only – not for use in product promotion The US Obesity Pharmacotherapy Market is Growing with Introduction of Branded Products 6% 11% 537% 107% 2014E 2014E Source: IMS Data

  16. Slide 16: Mysimba is First Weight Management Drug to Receive Positive CHMP Opinion in Nearly a Decade

    Slide 16: Mysimba is First Weight Management Drug to Receive Positive CHMP Opinion in Nearly a Decade

    For investor purposes only – not for use in product promotion Mysimba™ is First Weight Management Drug to Receive Positive CHMP Opinion in Nearly a Decade Positive CHMP opinion December 2014 EU authorization expected February 2015 Expected to be one of two oral weight management drugs on market in E

  17. Slide 17: Significant ex-US Sales Potential for Contrave / Mysimba

    Slide 17: Significant ex-US Sales Potential for Contrave / Mysimba

    For investor purposes only – not for use in product promotion Ex-US Historic Anti-Obesity Sales in 2007 ~ $1.4 billion Europe 43% ROW 57% Historic Anti-Obesity Sales in select countries Significant ex-US Sales Potential for Contrave ® / Mysimba™ Country Sales (2007) Middle East $54.2M Russia $48.8M

  18. Slide 18: Life Cycle Development Opportunities for Contrave / Mysimba

    Slide 18: Life Cycle Development Opportunities for Contrave / Mysimba

    For investor purposes only – not for use in product promotion Exciting Life Cycle Development Opportunities for Contrave ® / Mysimba™ Fixed dose combination with an approved diabetes drug, e.g., DPP4 and/or SGLT2 – Attractive opportunity under evaluation for patients with diabetes who are overweight

  19. Slide 19: Broad and Growing Patent Estate Could Yield Protection Through 2034

    Slide 19: Broad and Growing Patent Estate Could Yield Protection Through 2034

    Binge Eating (methods) Major Depression (methods) Visceral Fat (methods) Titration / Dose Pack (methods & devices) Tri-layer (methods & compositions) Food Cravings / Titration (methods) Insulin Sensitivity (methods & compositions) Weber / Cowley (methods & compositions) Nal SR (methods & composition

  20. Slide 20: Solid Financial Position

    Slide 20: Solid Financial Position

    For investor purposes only – not for use in product promotion Solid Financial Position Revenue drivers Tiered royalties of 20-35% on net sales in North America $15 million anniversary milestones to be paid in 2015, 2016, 2017 Potential sales milestones up to $880M Proceeds from potential ROW partner

  21. Slide 21: 2015 Focus for Orexigen

    Slide 21: 2015 Focus for Orexigen

    For investor purposes only – not for use in product promotion 2015 Focus for Orexigen Successful US launch EU approval and ROW licensing Continue to strengthen patent portfolio Lifecycle development programs

  22. Slide 22: Orexigen

    Slide 22: Orexigen

    is OREXIGEN

Source: SEC EDGAR · 8-K filed Jan 12, 2015

More decks from Orexigen Therapeutics Inc